Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Hailey Hailey Disease
NCT06651489Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of guselkumab in Hailey-Hailey disease (HHD), sponsored by Yale University. Started Mar 2025; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Hailey-Hailey disease (HHD)
Beyond the preview
Go deeper on NCT06651489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651489.